SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Bristol Myers Squibb Co. – ‘8-K’ for 3/1/21 – ‘XML’

On:  Thursday, 3/4/21, at 4:30pm ET   ·   For:  3/1/21   ·   Accession #:  1140361-21-7317   ·   File #:  1-01136

Previous ‘8-K’:  ‘8-K’ on 2/23/21 for 2/19/21   ·   Next:  ‘8-K’ on / for 4/29/21   ·   Latest:  ‘8-K’ on 3/18/24 for 3/13/24   ·   9 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/04/21  Bristol Myers Squibb Co.          8-K:5,9     3/01/21   11:212K                                   Edgarfilings Ltd.

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     31K 
 7: R1          Document and Entity Information                     HTML     57K 
 9: XML         IDEA XML File -- Filing Summary                      XML     12K 
 6: XML         XBRL Instance -- brhc10021324_8k_htm                 XML     25K 
 8: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 3: EX-101.DEF  XBRL Definitions -- bmy-20210301_def                 XML     52K 
 4: EX-101.LAB  XBRL Labels -- bmy-20210301_lab                      XML     79K 
 5: EX-101.PRE  XBRL Presentations -- bmy-20210301_pre               XML     56K 
 2: EX-101.SCH  XBRL Schema -- bmy-20210301                          XSD     17K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               16±    22K 
11: ZIP         XBRL Zipped Folder -- 0001140361-21-007317-xbrl      Zip     14K 


‘XML’   —   XBRL Instance — brhc10021324_8k_htm


This Document is an XBRL XML File.


                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:bmy="http://bms.com/20210301" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink">
<link:schemaRef xlink:href="bmy-20210301.xsd" xlink:type="simple"/>
<context id="c20210301to20210301">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000014272 </identifier>
</entity>
<period>
<startDate> 2021-03-01 </startDate>
<endDate> 2021-03-01 </endDate>
</period>
</context>
<context id="c20210301to20210301_StatementClassOfStockAxis_CelgeneContingentValueRightsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000014272 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> bmy:CelgeneContingentValueRightsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-03-01 </startDate>
<endDate> 2021-03-01 </endDate>
</period>
</context>
<context id="c20210301to20210301_StatementClassOfStockAxis_One750NotesDue2035Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000014272 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> bmy:One750NotesDue2035Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-03-01 </startDate>
<endDate> 2021-03-01 </endDate>
</period>
</context>
<context id="c20210301to20210301_StatementClassOfStockAxis_One000NotesDue2025Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000014272 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> bmy:One000NotesDue2025Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-03-01 </startDate>
<endDate> 2021-03-01 </endDate>
</period>
</context>
<context id="c20210301to20210301_StatementClassOfStockAxis_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000014272 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-03-01 </startDate>
<endDate> 2021-03-01 </endDate>
</period>
</context>
<dei:AmendmentFlag contextRef="c20210301to20210301" id="Fact_b83ae43e78e44336ad8457db9e13061f"> false </dei:AmendmentFlag>
<dei:EntityCentralIndexKey contextRef="c20210301to20210301" id="Fact_9d8260d2d028403185510a629bae949e"> 0000014272 </dei:EntityCentralIndexKey>
<dei:DocumentType contextRef="c20210301to20210301" id="Fact_9b4e5416edb64ddc882c4ef58f8d8ef8"> 8-K </dei:DocumentType>
<dei:DocumentPeriodEndDate contextRef="c20210301to20210301" id="Fact_e6e364a2c91c4b1599fd22cc8b1c521d"> 2021-03-01 </dei:DocumentPeriodEndDate>
<dei:EntityRegistrantName contextRef="c20210301to20210301" id="Fact_cf20d772d6e64530bd15b5874e69d9b4"> BRISTOL-MYERS SQUIBB COMPANY </dei:EntityRegistrantName>
<dei:EntityIncorporationStateCountryCode contextRef="c20210301to20210301" id="Fact_3ba010766e9f4a1faa6bad8641bc2dac"> DE </dei:EntityIncorporationStateCountryCode>
<dei:EntityFileNumber contextRef="c20210301to20210301" id="Fact_590b14d48b994d18ae0a17adf89e7481"> 001-01136 </dei:EntityFileNumber>
<dei:EntityTaxIdentificationNumber contextRef="c20210301to20210301" id="Fact_6fa24fb9450942e99a0635163d628a0e"> 22-0790350 </dei:EntityTaxIdentificationNumber>
<dei:EntityAddressAddressLine1 contextRef="c20210301to20210301" id="Fact_55bfeb4cbcec4e489882faf377d7b1e3"> 430 East 29th Street </dei:EntityAddressAddressLine1>
<dei:EntityAddressAddressLine2 contextRef="c20210301to20210301" id="Fact_a99eaaadd83d47f8af2d93619198aa58"> 14th Floor </dei:EntityAddressAddressLine2>
<dei:EntityAddressCityOrTown contextRef="c20210301to20210301" id="Fact_baf0edc3c5244e48a64767fde27ac811"> New York </dei:EntityAddressCityOrTown>
<dei:EntityAddressStateOrProvince contextRef="c20210301to20210301" id="Fact_b20559a07ea84ded840438da6eef4fef"> NY </dei:EntityAddressStateOrProvince>
<dei:EntityAddressPostalZipCode contextRef="c20210301to20210301" id="Fact_c200207de4f9470f8c8f7a510e67b2ba"> 10016 </dei:EntityAddressPostalZipCode>
<dei:CityAreaCode contextRef="c20210301to20210301" id="Fact_7195527f295842cda279267dc3d90921"> 212 </dei:CityAreaCode>
<dei:LocalPhoneNumber contextRef="c20210301to20210301" id="Fact_baf0efae5e9d423b8dc6f4fed6e57a73"> 546-4000 </dei:LocalPhoneNumber>
<dei:WrittenCommunications contextRef="c20210301to20210301" id="Fact_2674c13451f64c80808d19a155b21c81"> false </dei:WrittenCommunications>
<dei:SolicitingMaterial contextRef="c20210301to20210301" id="Fact_bff6fe4b3f5f4ae09b663e3759b28e23"> false </dei:SolicitingMaterial>
<dei:PreCommencementTenderOffer contextRef="c20210301to20210301" id="Fact_bdddaf003f4941f0babc197f3f7ad6de"> false </dei:PreCommencementTenderOffer>
<dei:PreCommencementIssuerTenderOffer contextRef="c20210301to20210301" id="Fact_e179e90892f843ab920092c2e86ff123"> false </dei:PreCommencementIssuerTenderOffer>
<dei:Security12bTitle contextRef="c20210301to20210301_StatementClassOfStockAxis_CommonStockMember" id="Fact_4c27a76880e24ddb8bf6a4796331bcc3"> Common Stock, $0.10 Par Value </dei:Security12bTitle>
<dei:TradingSymbol contextRef="c20210301to20210301_StatementClassOfStockAxis_CommonStockMember" id="Fact_1759c2c871484f2fb0e5265cc3776f24"> BMY </dei:TradingSymbol>
<dei:SecurityExchangeName contextRef="c20210301to20210301_StatementClassOfStockAxis_CommonStockMember" id="Fact_5a30b5eb1a924b97bb9fbcdcf2eaac09"> NYSE </dei:SecurityExchangeName>
<dei:Security12bTitle contextRef="c20210301to20210301_StatementClassOfStockAxis_One000NotesDue2025Member" id="Fact_fa1f441663354d47ae7daea26734552d"> 1.000% Notes due 2025 </dei:Security12bTitle>
<dei:TradingSymbol contextRef="c20210301to20210301_StatementClassOfStockAxis_One000NotesDue2025Member" id="Fact_2907466adaa149eab77401c4d9df02ff"> BMY25 </dei:TradingSymbol>
<dei:SecurityExchangeName contextRef="c20210301to20210301_StatementClassOfStockAxis_One000NotesDue2025Member" id="Fact_57b5da668db44607aff37597b2bda83f"> NYSE </dei:SecurityExchangeName>
<dei:Security12bTitle contextRef="c20210301to20210301_StatementClassOfStockAxis_One750NotesDue2035Member" id="Fact_9f987dd2b3f54a4f8daddc6124112efb"> 1.750% Notes due 2035 </dei:Security12bTitle>
<dei:TradingSymbol contextRef="c20210301to20210301_StatementClassOfStockAxis_One750NotesDue2035Member" id="Fact_e55a55b63c1e455aae15e09fd794f3b0"> BMY35 </dei:TradingSymbol>
<dei:SecurityExchangeName contextRef="c20210301to20210301_StatementClassOfStockAxis_One750NotesDue2035Member" id="Fact_37cb6d5161274a6a8aef0f706224b65e"> NYSE </dei:SecurityExchangeName>
<dei:Security12bTitle contextRef="c20210301to20210301_StatementClassOfStockAxis_CelgeneContingentValueRightsMember" id="Fact_9dc9f7e9bd714976be746bad5dfaccfc"> Celgene Contingent Value Rights </dei:Security12bTitle>
<dei:TradingSymbol contextRef="c20210301to20210301_StatementClassOfStockAxis_CelgeneContingentValueRightsMember" id="Fact_5eb59afdfea946b5a101dacdc7627193"> CELG RT </dei:TradingSymbol>
<dei:SecurityExchangeName contextRef="c20210301to20210301_StatementClassOfStockAxis_CelgeneContingentValueRightsMember" id="Fact_1a57d6df13e44f8b8313a2f403c2a541"> NYSE </dei:SecurityExchangeName>
<dei:EntityEmergingGrowthCompany contextRef="c20210301to20210301" id="Fact_f21400248d224812bd5fc88fe793a59e"> false </dei:EntityEmergingGrowthCompany>
</xbrl>


9 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/16/24  Bristol-Myers Squibb Co.          424B5                  2:1.2M                                   Broadridge Fin’l So… Inc
 2/13/24  Bristol-Myers Squibb Co.          424B2                  1:856K                                   Broadridge Fin’l So… Inc
11/01/23  Bristol-Myers Squibb Co.          424B5                  2:927K                                   Broadridge Fin’l So… Inc
10/30/23  Bristol-Myers Squibb Co.          424B3                  1:818K                                   Broadridge Fin’l So… Inc
 2/17/22  Bristol-Myers Squibb Co.          424B5                  2:878K                                   Broadridge Fin’l So… Inc
 2/15/22  Bristol-Myers Squibb Co.          424B3                  1:789K                                   Broadridge Fin’l So… Inc
12/13/21  Bristol-Myers Squibb Co.          S-3ASR     12/13/21    4:554K                                   Broadridge Fin’l So… Inc
 5/04/21  Bristol-Myers Squibb Co.          S-8         5/04/21    3:81K                                    Broadridge Fin’l So… Inc
 5/04/21  Bristol-Myers Squibb Co.          S-8 POS     5/04/21    3:85K                                    Broadridge Fin’l So… Inc
Top
Filing Submission 0001140361-21-007317   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Mar. 29, 10:13:11.2am ET